Eli Lilly报告溃疡性结肠炎试验的阳性结果

Eli Lilly (NYSE:LLY) announced positive results from a late-stage trial of Omvoh (mirikizumab-mrkz) for patients suffering from moderately to severely active ulcerative colitis.

The study demonstrated that patients could achieve sustained, long-term outcomes over a four-year period.

In the LUCENT-3 study, around 80% of patients treated with Omvoh who reached clinical remission after one year were able to maintain their remission without the need for corticosteroids. 

After four years, nearly all patients who had achieved remission at the one-year mark reported improvements in bowel urgency, a symptom that significantly impacts their quality of life.

The company said that the long-term safety profile for Omvoh in these patients remained consistent with previously established safety data, with no new safety concerns identified during the trial.